Sheffield, UK, July 1 2025 – Rinri Therapeutics, a world leading company focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, is pleased to announce the approval ...
MK-3000, a tri-specific antibody, is being tested in the BRUNELLO trial for diabetic macular edema, following positive ...
ProQR Therapeutics announces a Phase 1 trial of AX-0810 to evaluate safety and target engagement in cholestatic liver disease. The initiation of the Phase 1 clinical trial for AX-0810 is contingent ...
First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGen Trial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, ...
Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK) ...
First-in-Human Trial Shows Promising Results for DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer (Barcelona, Spain Sunday, September 7, 2025 at 4:45 PM CEST / UTC +2) ...
A city research centre plans to use tomatoes to test the impact of gene-edited food in what is thought to be the first human ...
VANCOUVER, BC / ACCESS Newswire / August 4, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce it has entered into ...
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the"Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline ...
Please provide your email address to receive an email when new articles are posted on . Two different gene-edited pig kidneys have been successfully transplanted into living human patients under FDA’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback